Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Ensure it is kept in a cool, dry place and follow any airline regulations regarding needles and vials
In HFF, patients followed for HBV between 2012 and 2022 were included
4710-C PNPLA3 GENOTYPE IS ASSOCIATED WITH RISK OF HCC BUT NOT DECOMPENSATION IN PATIENTS WITH COMPENSATED CIRRHOSIS Esteban Urias 1 , Nicholas Tedesco 1 , Karn Wijarnpreecha 2 and Vincent Chen 3 , (1)University of Michigan, (2)University of Arizona College of Medicine Phoenix, Phoenix, AZ, (3)University of Michigan Medical Center Background: The PNPLA3 -rs738409-G, TM6SF2 -rs58542926-T, and HSD17B13 -rs6834314-A polymorphisms have been associated with cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC)
Methods: Samples were collected at 4 weekly intervals from the initial screening test until primary endpoint (week 24 post-randomization) with a final sample at the end of the extension period (week 48)
Some patients have metabolic risk factors associated with MAFLD such as Type 2 Diabetes
US$ 20.10
US$ 28.86
US$ 29.89
US$ 25.98
